Related content

XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a secondline setting involving the sequential administration of XELOX and XELIRI

By                        

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 827-832

Spandidos Publications

Access to resources Recommend Favorite

Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the firstline treatment of metastatic colorectal cancer

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 166-170

Spandidos Publications

Access to resources Recommend Favorite

KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin or irinotecanbased treatment

By                  

Molecular and Clinical Oncology, Vol. 2, Iss. 3, 2014-01 ,pp. : 356-362

Spandidos Publications

Access to resources Recommend Favorite

Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis

By Nebuloni  

Molecular and Clinical Oncology, Vol. 1, Iss. 1, 2013-01 ,pp. : 175-179

Spandidos Publications

Access to resources Recommend Favorite

Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study

By Atta Elias   Dias Danielle   Marra Vera   Azevedo Alexandre  

Annals of Hematology, Vol. 89, Iss. 9, 2010-09 ,pp. : 851-859

Springer Publishing Company

Access to resources Recommend Favorite